AZN vs NYXH

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

NYXH exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. While the company shows explosive revenue growth (346.90% YoY) and maintains a strong gross margin of 63.13%, these are overshadowed by an unsustainable operating margin of -329.29% and a consistent track record of earnings misses. The stock is technically in a freefall with a 0/100 trend score and a 1-year price decline of 43.6%. Despite bullish analyst price targets, the deterministic data suggests a high-risk speculative profile with significant capital erosion.